In this enlightening episode, Anthony and Bernie chat about FLT3+ AML with Dr. Dale Bixby, Clinical Professor and expert in leukemia at the University of Michigan. We use two clinical cases to take a deep dive into the biology and prognostic implications of FLT3+ AML, pitfalls and controversies of variant allele frequency and allelic ratio testing, and the data that informs the use of FLT3 inhibitors in AML. Watch out for some possibly heretical views!

REFERENCES

Schlenk and Dohner (Impact of AML prognostic markers)l: https://pubmed.ncbi.nlm.nih.gov/19468271/

RATIFY Trial: https://www.nejm.org/doi/full/10.1056/nejmoa1614359

QUANTUM-FIRST: https://library.ehaweb.org/eha/2022/eha2022-congress/356965/harry.erba.quizartinib.prolonged.survival.vs.placebo.plus.intensive.induction.html?f=menu%3D6%2Abrowseby%3D8%2Asortby%3D2%2Amedia%3D3%2Ace_id%3D2233%2Amarker%3D1749%2Afeatured%3D17676

ODAC Review of Quantum-R (quizartinib): https://www.fda.gov/media/124896/download

ELN 2022: https://pubmed.ncbi.nlm.nih.gov/35797463/

WHO Myeloid 2022: https://pubmed.ncbi.nlm.nih.gov/35732831/

Sorafenib Maintenance (RCT China): https://pubmed.ncbi.nlm.nih.gov/32791048/

SorMAIN: https://pubmed.ncbi.nlm.nih.gov/32673171/

RADIUS (midostaurin maintenance): https://pubmed.ncbi.nlm.nih.gov/33288862/

LACEWING Trial: https://pubmed.ncbi.nlm.nih.gov/35917453/

HMA/Ven pooled FLT3: https://pubmed.ncbi.nlm.nih.gov/35063965/

Ven/Aza/Gilteritinib ASH 2022: https://ash.confex.com/ash/2022/webprogram/Paper157210.html

UK NCRI AML 17 Flt3 analysis: https://pubmed.ncbi.nlm.nih.gov/27268085/